Alto Neuroscience (NYSE:ANRO) Hits New 12-Month High Following Strong Earnings

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price hit a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $29.70 and last traded at $29.19, with a volume of 97651 shares. The stock had previously closed at $28.78.

The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ANRO shares. Wedbush raised their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday. Bank of America started coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. BTIG Research raised their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wolfe Research began coverage on Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.62.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Commodore Capital LP grew its position in Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after purchasing an additional 900,000 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after buying an additional 225,500 shares during the period. Armistice Capital LLC grew its holdings in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after buying an additional 12,000 shares in the last quarter. Finally, Spruce Street Capital LP raised its stake in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after acquiring an additional 1,102,366 shares in the last quarter.

Alto Neuroscience Stock Up 12.2%

The company has a market cap of $1.15 billion, a price-to-earnings ratio of -13.53 and a beta of 1.06. The stock has a 50-day simple moving average of $25.70 and a 200-day simple moving average of $22.68. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.